GlassScriptPhysician profile
Shari K Carter
NPI 1457383317
$2,672.66
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,139 · 2022: $1,421 · 2023: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $112.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.28 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.88 | 2021-2022 | |
| Abbvie INC. | $341.85 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $244.27 | 2021-2022 | |
| Esperion Therapeutics, INC. | $166.15 | 2021 | |
| Glaxosmithkline, LLC. | $137.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $135.69 | 2021-2022 | |
| Amarin Pharma, INC. | $117.36 | 2021 | |
| Boston Scientific Corporation | $112.79 | 2023 | Wavewriter Alpha Prime 16, Rezum Generator |
| Lilly USA, LLC | $109.32 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $77.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.47 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.94 | 2021-2022 | |
| Pfizer INC. | $50.54 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.72 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $42.94 | 2021 | |
| Daiichi Sankyo INC. | $41.22 | 2021-2022 | |
| Abbott Laboratories | $35.82 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.92 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.30 | 2022 | |
| Mylan Specialty L.P. | $18.81 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.37 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.